Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its groundbreaking oral GLP-1 receptor agonist pill, directly to consumers across the United States through the LillyDirect cash-pay channel, telehealth providers, and pharmacies. This move marks a significant step in making once-daily oral obesity treatments more accessible, to be used alongside a reduced-calorie diet and increased physical activity, as stated by the pharmaceutical company.
What is Foundayo and How Does It Work?
Foundayo (orforglipron) is Eli Lilly's once-daily oral formulation of a GLP-1 receptor agonist, designed specifically for obesity management. GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which is naturally released in the gut after eating. This action helps regulate blood sugar, slows gastric emptying to promote feelings of fullness, and reduces appetite signals in the brain, leading to meaningful weight loss when combined with lifestyle changes.
Unlike injectable GLP-1 drugs that require weekly or daily shots, Foundayo's pill form offers a convenient alternative, potentially improving patient adherence. Clinical data highlighted by Eli Lilly shows an average of 27 pounds of weight loss at the highest dose, underscoring its efficacy in tackling obesity—a condition affecting over 40% of U.S. adults.
FDA Approval and Historic Launch Details
The U.S. Food and Drug Administration (FDA) cleared Foundayo on April 1, designating it as the first new molecular entity approved under the regulator's Commissioner's National Priority Voucher (CNPV) program, according to Fierce Pharma. This approval paves the way for widespread distribution, emphasizing Eli Lilly's commitment to innovative delivery methods in the GLP-1 space.
The launch through LillyDirect provides free home delivery, simplifying the path from prescription to doorstep. As Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, stated:
"Foundayo delivers meaningful weight loss - an average of 27 pounds at the highest dose - and we made the path from prescription to doorstep as simple as possible. Millions of Americans can now connect with a health care professional to determine if Foundayo is right for them and receive the medicine at their door through LillyDirect's free home delivery, or access it through telehealth providers or local retail pharmacies."
Why Oral GLP-1 Drugs Matter for Metabolic Health
Oral GLP-1 medications like Foundayo represent a leap forward in peptide therapy for metabolic health. They address barriers to treatment adherence seen with injectables, such as needle phobia or inconvenience. For patients with obesity-related comorbidities like type 2 diabetes or cardiovascular risk, these drugs not only promote weight loss but also offer broader cardiometabolic benefits, including improved insulin sensitivity and lipid profiles.
Pricing and Insurance Coverage for Foundayo
Accessibility is a core focus of the launch. For patients with commercial insurance, Foundayo could cost as little as $25 per month with a savings card. Self-pay options start at $149 a month for the lowest dose. Medicare Part D users may access it for $50 beginning July 1, per Eli Lilly's announcement.
These competitive prices position Foundayo favorably in a market where GLP-1 costs have been a barrier. Patients should consult their healthcare provider and insurer to confirm coverage, as formularies vary.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Expanded Access Through Telehealth and Pharmacy Partners
Eli Lilly's strategy extends beyond LillyDirect, partnering with a network of telehealth and pharmacy services for broad reach.
- Amazon Pharmacy: Customers with valid prescriptions can order Foundayo, including through same-day delivery in nearly 3,000 areas, expanding to 4,500 municipalities by the end of 2026. It's also available via in-clinic kiosks at One Medical locations post-appointment.
- GoodRx: Eligible self-pay patients access it "in line with the lowest available discounted cash price at launch," per their April 9 announcement. GoodRx is also expanding to Lilly's Zepbound Quickpen for $299 per month at over 70,000 pharmacies.
- Ro: Available for $149 per month at the lowest dose, though additional membership fees apply.
- Weight Watchers Med+: Now offered to members, integrating with their coaching programs.
This multi-channel approach ensures patients in urban and rural areas alike can obtain Foundayo quickly, often without traditional in-person visits.
Competition with Novo Nordisk in the GLP-1 Market
The launch intensifies rivalry with Novo Nordisk, which pioneered injectable Wegovy and recently introduced discounted Wegovy subscription plans. Despite being first to market with both injectable and oral Wegovy formulations, Novo has ceded its superior obesity market share in the U.S. to Lilly, reports Fierce Pharma.
Foundayo vs. Wegovy: Key Comparisons
| Feature | Foundayo (Eli Lilly) | Wegovy (Novo Nordisk) |
|---|---|---|
| Dosage Form | Once-daily oral pill | Weekly injection (oral version available) |
| Access Channels | LillyDirect, Amazon, Ro, GoodRx | Subscription plans, pharmacies |
| U.S. Market Share | Gaining lead | Previously dominant |
Foundayo's oral convenience and pricing may tip the scales, especially for patients preferring non-injectable options.
Safety, Side Effects, and Patient Guidance
As with all GLP-1 receptor agonists, Foundayo is prescribed alongside diet and exercise. Common side effects of this class include nausea, diarrhea, and gastrointestinal discomfort, which often diminish over time. Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1s.
Before starting, discuss with a healthcare provider to assess suitability. Tools like Shotlee can help track symptoms, side effects, or medication schedules during treatment initiation.
Key Takeaways: What This Means for Patients
- Foundayo offers convenient oral GLP-1 therapy with proven weight loss (average 27 lbs at highest dose).
- Multiple access points: LillyDirect (free delivery), Amazon same-day, GoodRx discounts, Ro, and more.
- Affordable pricing: $25/month insured, $149 self-pay lowest dose.
- Consult a doctor to see if it's right for your obesity management plan.
Conclusion
Eli Lilly's launch of Foundayo via LillyDirect and telehealth partners democratizes access to oral GLP-1 therapy, challenging the status quo in obesity treatment. By preserving efficacy with enhanced convenience, it empowers millions to achieve sustainable weight loss. Speak with your provider today to explore if Foundayo fits your metabolic health goals.
